Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered stem cells aim to speed recovery in blood cancer patients

NCT ID NCT04260698

Disease control Sponsor: Gamida Cell ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests omidubicel, an experimental stem cell transplant, for people with high-risk blood cancers like leukemia or lymphoma. The goal is to see if it helps the body rebuild its immune system faster after transplant. Participants receive omidubicel along with standard transplant care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
omidubicel (stem cell transplant)
What this could lead to
If successful, omidubicel could help patients with blood cancers recover their immune system faster after a stem cell transplant, potentially reducing complications.
What could go wrong
This is an early expanded access study with a small number of participants. The treatment may not work for everyone, and stem cell transplants carry risks like infection and graft failure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

36 people

The number who actually took part.

Started

Jul 2020

Finished

May 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients must be at least 12 years of age * Applicable disease criteria * Patients must have one or two partially HLA-matched CBUs * Back-up stem cell source * Sufficient physiological reserves * Females of childbearing potential agree to use appropriate method of contraception * Signed written informed consent Exclusion Criteria: * Extensive bone marrow fibrosis * Donor specific anti-HLA antibodies * Pregnancy * Medically unsuitable for transplant

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hematological malignancies are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hematological malignancies

Contacts and locations

Locations

  • Duke University Medical Center

    Durham, North Carolina, 27710, United States

  • Loyola University, Cardinal Bernardin Cancer Center

    Maywood, Illinois, 60153, United States

  • Oregon Health & Science University

    Portland, Oregon, 97239, United States

  • Stanford University Cancer Institute

    Palo Alto, California, 94063, United States

  • UCLA

    Los Angeles, California, 90095, United States

  • University of Minnesota Masonic Cancer Center

    Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.